Breaking News, Collaborations & Alliances

Selexis, Turgut Expand Biosimilar Development Pact

Under new commercial license agreements, Selexis will help advance Turgut’s pipeline of biosim products in oncology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Selexis SA and Turgut Pharmaceuticals have signed two commercial license agreements (CLAs) through which Turgut will leverage Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for the development of two biosimilar antibodies: a checkpoint inhibitor for the treatment of certain cancers and a monoclonal antibody for the treatment of metastatic HER2-positive breast cancer. With the addition of these CLAs, the companies are now working together to develop multiple biosimilar products in canc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters